Revenue segments as reported by the company.

Products

Premiums

Services

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit costs

Operating expenses

Goodwill impairment

Store impairments

Opioid litigation charges

Loss on assets held for sale

Restructuring charge

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CVS Health

Aetna is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.

Aetna

CVS Pharmacy is a subsidiary of the American retail and health care company CVS Health, headquartered in Woonsocket, Rhode Island. It was also known as, and originally named the Consumer Value Store and was founded in Lowell, Massachusetts, in 1963. The chain was owned by its original holding company Melville Corporation since its inception until its current parent company CVS Health was spun off into its own company in 1996. CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations (over 9,600 as of 2016) and total prescription revenue. As the retail pharmacy division of CVS Health, it ranks as the 7th largest U.S. corporation according to Fortune 500 in 2016. CVS Pharmacy's leading competitor Walgreens Boots Alliance ranked 37th.

CVS Pharmacy

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVS Health exceeds Q4 expectations, eyes growth with Oak Street

CVS Health's strong financial performance in 2022, driven by revenue growth and exceeding EPS expectations, positions the company well for future growth.
The acquisition of Oak Street Health presents opportunities to expand into primary care and improve long-term earnings growth, despite challenges in maintaining retail performance.

CVS Health excels in Q1, eyes growth through acquisitions and innovation

CVS Health's strong financial performance, strategic acquisitions, and customer-centric initiatives position the company for sustained growth and competitive advantage.
While facing challenges in the evolving healthcare landscape, CVS Health's focus on innovation, affordability, and operational efficiency provides a solid foundation for future success.
By capitalizing on opportunities in growth, synergies, and healthcare services, CVS Health can navigate industry headwinds and drive long-term value creation for stakeholders.

CVS Health reports robust Q2 earnings, eyes growth opportunities

CVS Health's Q2 2023 performance reflects strong financial results and strategic acquisitions driving growth.
Despite challenges like higher costs and restructuring charges, the company remains confident in its ability to deliver outstanding performance.
Opportunities lie in expanding Medicaid contracts, biosimilar market establishment, and clinic openings for at-risk populations.
Overall, CVS Health's focus on cost optimization, digital sales growth, and patient engagement positions it well for future success.

CVS Health reports robust Q3 earnings and strategic growth plans

CVS Health's Q3 performance reflects strong financial results and strategic initiatives across its segments, positioning the company for sustainable growth.
While facing challenges like declining vaccine demand and contract losses, CVS Health is focused on leveraging opportunities in biosimilars and cost-saving solutions.
The company's commitment to operational excellence, innovation, and workforce investment underscores its strategic vision for becoming a leading health solutions provider.
With a clear focus on growth drivers and mitigating challenges, CVS Health is poised to capitalize on market opportunities and deliver value to shareholders.

CVS Health reports robust Q4 earnings, eyes Medicare margin recovery

CVS Health's Q4 2023 earnings call highlighted strong financial performance, a cautious stance on Medicare Advantage utilization, and a focus on transforming healthcare delivery. The company is committed to margin recovery, growth, and enhancing customer experience while addressing challenges in Medicare Advantage trends and cost pressures.

CVS Health faces Medicare Advantage challenges, focuses on margin improvement

CVS Health's Q1 2024 earnings call highlighted strong financial performance, challenges in the Medicare Advantage business, and a focus on improving margins. The company showcased strengths in the biosimilar market and Pharmacy & Consumer Wellness segment while addressing issues impacting Health Care Benefits and Services segments.

CVS Health's Q2 2024 performance reflects strong financial results, cost savings, and innovative initiatives in pharmacy services.
The company faces challenges in the Health Care Benefits segment but is actively addressing them through leadership changes and operational improvements.
Opportunities for growth include driving margin improvements, expanding digital reach, and educating stakeholders on the value delivery of PBMs.
Expectation of margin recovery in Medicare Advantage and double-digit EPS growth in 2025 highlight CVS Health's strategic focus on operational efficiencies and cost savings.

CVS Health reports robust Q3 earnings, focuses on growth strategies

CVS Health's Q3 2024 performance was marked by strong financial results, leadership changes, and segment-specific challenges and successes. The company is focused on leveraging opportunities in strategic initiatives and addressing areas for improvement to drive future growth.

Revenue

Cost of revenue

Gross profit

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol-Myers

B&G Foods

Verizon

With risk omnipresent in the market and more reason than 1 to fear a recession, value, yield, and beta are more critical for successful investing than ever. If nothing else, volatility should be expected until early Q2 2024, and those stocks trading at elevated valuations stand to lose the most.

High-yield, low-beta value plays for buy-and-hold investors

Archer-Daniels-Midland Company

Dow Inc

Energy Transfer LP Unit

Ford Motor Company

ManpowerGroup

MetLife

Omnicom Group

Pfizer

Philip Morris

Southern Company

Exxon Mobil

The Summer, 2023 edition of Fortune Magazine revealed 500 biggest U.S. companies by revenue. Dogcatcher's quest to sniff-out the best dividend buys focused on 68 industry leaders using YCharts 11/8/23. Those 68 industry leaders were segmented into 21 business sectors ranging (alphabetically) from apparel to wholesalers. Three of the 68 are not listed on U.S. exchanges. Their data was excluded. 58 dividend yielding stocks led those 68 industry leaders and ranged 0.19% to 9.56% in annual-yield and ranged -1.29% to 54.34% in broker-estimated one-year price-target-upsides by YCharts 11/8/23 reckoning.

5 Fair-Priced November Fortune 500 Industry-Leader Dogs Out Of 68

Starbucks

T-Mobile US

A dividend growth stock has a much better chance of outperforming the market than a non-payer. A low yield today could become a massive cash cow in just a few years.

3 Excellent Dividend Growth Stocks That Show No Signs of Slowing Down

Walgreens

CVS (CVS) and Walgreens (WBA) shares lost ground Wednesday after IAM Healthcare, a subsection of the International Association of Machinists and Aerospace Workers (IAM), launched The Pharmacy Guild, an effort to unite pharmacy workers who are calling for staffing and workload safety standards.

CVS and Walgreens Shares Fall After Pharmacy Guild Launches With Call to Unionize

The Pharmacy Guild aims to help staff unionize to address what employees have called unsafe working conditions, including at Walgreens and CVS.

Pharmacy walkout organizers help launch national push to unionize pharmacists, technicians

Humana

UnitedHealth Group

Buy-and-hold investing may seem like a boring activity, but it is the path to sustained wealth building. Building positions over time that leverage growth, capital returns, and capital return growth results in accelerating returns and market-beating performance.

3 healthy dividend stocks for buy and hold investors

WOONSOCKET, R.I. , Nov. 7, 2023 /PRNewswire/ -- CVS Health (NYSE: CVS) will hold its Investor Day on December 5th, 2023, in Boston, MA.

CVS Health to hold Investor Day on December 5, 2023

Perficient

Tenable Holdings Inc

The market has begun to rebound in recent days due to the U.S. Federal Reserve keeping interest rates steady, signaling the rate hike cycle has possibly come to an end. This is a welcome change since the sharp sell-off that began in late July triggered by inflation fears and the potential impact on elevated rates on economic growth and company earnings.

Don't Get Stuck with These 3 Declining Stocks

If any health crisis has been in the news over the last few years, it has been the opioid crisis, and while it's been somewhat pushed aside due to mounting Fentanyl deaths attributed in part to the issues at the border, the toll taken over that period was tremendous.

6 Reasons To Avoid CVS (CVS) Stock Today

CVS Health stock dipped after the company reported third-quarter results on Nov. 1. CVS Health's largest operating segment lost a big client earlier this year.

CVS Health Is Down 27% This Year. Is the Stock a Buy on the Dip?

CVS Health's headwinds could only be temporary. UPS' CEO is optimistic about the company's prospects.

3 Beaten-Down, High-Yield Dividend Stocks That Wall Street Predicts Could Soar More Than 25% Over the Next 12 Months

CVS Health Corp and Walgreens Boots Alliance on Wednesday said that a work action by some U.S. pharmacists this week had minimal impact on operations, with most stores remaining open.

CVS and Walgreens say pharmacist work action had minimal impact

CVS Health delivered better-than-expected revenue and earnings for its third quarter of 2023. The pharmacy chain also lowered its full-year earnings outlook, however, citing elevated utilization trends within its Medicare Advantage business and lower-than-expected script volumes.

Why CVS Health Stock Dropped Today

Robust sales growth across all three operating segments drove CVS Health's (CVS) third-quarter results.

CVS Health (CVS) Q3 Earnings Surpass Estimates, Margins Up

CVS Health (CVS) posted better-than-expected results on gains in its health services business, but shares fell 1% in early trading Wednesday as the big pharmacy chain reduced its unadjusted profit guidance.

CVS's Results Beat Forecasts, but Shares Fall as It Cuts Full-Year Unadjusted EPS

CVS Health Corporation (CVS) Q3 2023 Earnings Call Transcript

Although the revenue and EPS for CVS Health (CVS) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

CVS Health (CVS) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

CVS Health Corp (NYSE:CVS) bobbed and weaved to put the best gloss on its third-quarter earnings update early on – only to see the stock flop 4.2% premarket. Okay, the good news was that the bottom-line numbers for the last three months exceeded the Street's expectations.

CVS shares drop 4.2% on guidance downgrade

AbbVie

Analog Devices

Applied Materials

Advanced Micro Devices

AMETEK

ANSYS

Broadcom

Bath and Body Works

ON Semiconductor

Tired of the S&P 500's three-month losing streak? Help might be on the way in November.

November Is The S&P 500's Best Month — 10 Stocks Rally Every Time

CVS Health reported third quarter net income of $2.2 billion thanks in part to contributions from its new healthcare services acquisitions.

CVS Health Profits Eclipse $2.2 Billion As Company Integrates New Provider Businesses

CVS revises lower its guidance range for diluted GAAP earnings per share for the third straight quarter.

CVS Earnings Top Estimates but Stock Drops as Outlook Slashed Again

CVS Health Corp.'s stock CVS was up 0.8% premarket Wednesday, after the drug store chain posted stronger-than-expected third-quarter earnings, shrugging off lower profit guidance for the full year. The company had net income of $2.265 billion, or $1.75 a share, for the quarter, after a loss of $3.399 billion, or $2.59 a share, in the year-earlier period.

CVS Health's stock up after earnings beat, but company lowers full-year EPS guidance

CVS Health Corp beat Wall Street estimates for quarterly profit on Wednesday as strength in its drugstores and pharmacy benefit management business offset higher-than-expected medical costs at its insurance unit.

CVS profit beats estimates on strong performance of pharmacy operations

WOONSOCKET, R.I. , Nov. 1, 2023 /PRNewswire/ -- CVS Health Corporation (NYSE: CVS) today announced operating results for the three months ended September 30, 2023.

CVS Health reports third quarter results

Pharmaceutical concern CVS Health Corp (NYSE:CVS) will enter the earnings confessional before the open tomorrow.

News for CVS Health Stock (CVS)